Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 27;16(13):2351.
doi: 10.3390/cancers16132351.

A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial Results

Alexa Childs  1 , Craig Gerrand  2 , Bernadette Brennan  3 , Robin Young  4 , Kenneth S Rankin  5 , Michael Parry  6 , Jonathan Stevenson  6 , Adrienne M Flanagan  2   7 , Rachel M Taylor  1 , Lorna Fern  1 , Dominique Heymann  8   9 , Filipa Vance  10 , Jenny Sherriff  11 , Saurabh Singh  12 , Rubina Begum  13 , Sharon L Forsyth  13 , Krystyna Reczko  13 , Kate Sparksman  13 , William Wilson  13 , Sandra J Strauss  1   7
Affiliations

A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial Results

Alexa Childs et al. Cancers (Basel). .

Abstract

There has been little change to the standard treatment for osteosarcoma (OS) over the last 25 years and there is an unmet need to identify new biomarkers and novel therapeutic approaches if outcomes are to improve. Furthermore, there is limited evidence on the impact of OS treatment on patient-reported outcomes (PROs). ICONIC (Improving Outcomes through Collaboration in Osteosarcoma; NCT04132895) is a prospective observational cohort study recruiting newly diagnosed OS patients across the United Kingdom (UK) with matched longitudinal collection of clinical, biological, and PRO data. During Stage 1, which assessed the feasibility of recruitment and data collection, 102 patients were recruited at 22 sites with representation from patient groups frequently excluded in OS studies, including patients over 50 years and those with less common primary sites. The feasibility of collecting clinical and biological samples, in addition to PRO data, has been established and there is ongoing analysis of these data as part of Stage 2. ICONIC will provide a unique, prospective cohort of newly diagnosed OS patients representative of the UK patient population, with fully annotated clinical outcomes linked to molecularly characterised biospecimens, allowing for comprehensive analyses to better understand biology and develop new biomarkers and novel therapeutic approaches.

Keywords: biomarkers; observational; osteosarcoma; quality of life; treatment.

PubMed Disclaimer

Conflict of interest statement

D.H. is co-chairman of the GEMO study group of bone metastases and has stock or stock options in AtlanTa (Saint-Herblain, France). J.S. (Jonathan Stevenson) has received payment or honoraria from Alder Orthopaedics and Implantcast and has a leadership or fiduciary role for the National Cancer Research Institute. KSR has received payment or honoraria from Stryker. R.M.T. has received funding and is an ambassador for Sarcoma UK. S.J.S. has received consulting fees from GSK and Ceridwen Oncology and has received support for attending meetings and/or travel from Adaptimmune. All other authors have no competing interests to declare. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
ICONIC trial design.
See this image and copyright information in PMC

References

    1. de Pinieux G., Karanian M., Le Loarer F., Le Guellec S., Chabaud S., Terrier P., Bouvier C., Batistella M., Neuville A., Robin Y.-M., et al. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE. 2021;16:e0246958. doi: 10.1371/journal.pone.0246958. - DOI - PMC - PubMed
    1. Whelan J.S., Jinks R.C., McTiernan A., Sydes M.R., Hook J.M., Trani L., Uscinska B., Bramwell V., Lewis I.J., Nooij M.A., et al. Survival from high-grade localised extremity osteosarcoma: Combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann. Oncol. 2012;23:1607–1616. doi: 10.1093/annonc/mdr491. - DOI - PMC - PubMed
    1. Tan G.J.S., Gerrand C.H., Rankin K.S. Blood-borne biomarkers of osteosarcoma: A systematic review. Pediatr. Blood Cancer. 2019;66:e27462. doi: 10.1002/pbc.27462. - DOI - PubMed
    1. Smeland S., Bielack S.S., Whelan J., Bernstein M., Hogendoorn P., Krailo M.D., Gorlick R., Janeway K.A., Ingleby F.C., Anninga J., et al. Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur. J. Cancer. 2019;109:36–50. doi: 10.1016/j.ejca.2018.11.027. - DOI - PMC - PubMed
    1. Eyre R., Feltbower R.G., James P.W., Blakey K., Mubwandarikwa E., Forman D., McKinney P.A., Pearce M.S., McNally R.J. The epidemiology of bone cancer in 0–39 year olds in northern England, 1981–2002. BMC Cancer. 2010;10:357. doi: 10.1186/1471-2407-10-357. - DOI - PMC - PubMed

LinkOut - more resources